Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study
Authors
Keywords
-
Journal
LIPIDS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-06-09
DOI
10.1002/lipd.12374
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
- (2022) Kyung-Soo Kim et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study
- (2021) Arnaud D. Kaze et al. Journal of the American Heart Association
- Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
- (2021) Henry N Ginsberg et al. EUROPEAN HEART JOURNAL
- Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa
- (2021) Lebohang Pitso et al. BMC Endocrine Disorders
- Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies
- (2019) Xiaofeng Ye et al. Cardiovascular Diabetology
- Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial
- (2018) Antonio J. Vallejo-Vaz et al. CIRCULATION
- Diabetes and lipid metabolism
- (2018) Vasilios G. Athyros et al. Hormones-International Journal of Endocrinology and Metabolism
- Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol
- (2018) Gregory A. Nichols et al. DIABETES OBESITY & METABOLISM
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
- (2018) Wenjun Fan et al. Journal of Clinical Lipidology
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2017) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Success Story of LDL Cholesterol Lowering
- (2016) Terje R. Pedersen CIRCULATION RESEARCH
- Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study
- (2015) P. C. Deedwania et al. DIABETES OBESITY & METABOLISM
- Pathophysiology of diabetic dyslipidaemia: where are we?
- (2015) Bruno Vergès DIABETOLOGIA
- Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
- (2015) Gregory G. Schwartz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Rodney A. Hayward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
- (2013) David C. Goff et al. CIRCULATION
- Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
- (2012) Anders Berg Jørgensen et al. EUROPEAN HEART JOURNAL
- Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
- (2011) Meng Lee et al. ATHEROSCLEROSIS
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
- (2011) Uchechukwu K. Sampson et al. Current Atherosclerosis Reports
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis
- (2010) Eric Bruckert et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention
- (2010) Kiran Musunuru LIPIDS
- Combination Lipid Therapy in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Management of dyslipidemia in people with type 2 diabetes mellitus
- (2010) Fredrick L. Dunn REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
- (2008) Jean-Charles Fruchart et al. Diabetes & Vascular Disease Research
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started